

# A Review on Clinical Approaches to The Management of Chronic Kidney Disease

Dr. Manchineni Prasada Rao\*<sup>1</sup>, Dr. Y. Narasimha Rao<sup>2</sup>, Dr. S. Rajini<sup>3</sup>, P. Mounika<sup>4</sup>

1. Dr. Manchineni Prasada Rao, Professor & principal.

2. Dr. Y. Narasimha Rao, Professor, Department of Pharmacology.

3. Dr. S. Rajini, Professor, Department of pharmacy practice.

4. P. Mounika, Pharm D Student.

M.A.M College of Pharmacy, Kesanupalli, Narasaraopet (522601), Palnadu district, Andhra Pradesh

Corresponding Author: Dr. Manchineni Prasada Rao

Date of Submission: 12-05-2026

Date of Acceptance: 27-05-2026

## Abstract

Chronic kidney disease (CKD) is a progressive and irreversible decline in renal function associated with substantial cardiovascular morbidity, mortality, and healthcare burden worldwide. Contemporary CKD management has evolved from supportive care to a multifaceted, evidence-based strategy integrating lifestyle modification, pharmacological interventions, risk-factor optimization, and prevention of complications. This review summarizes current clinical approaches to CKD management, emphasizing early diagnosis, slowing disease progression, cardiovascular risk reduction, and patient-centered care. Key interventions include dietary sodium restriction, protein optimization, blood pressure control, glycemic management, renin-angiotensin-aldosterone system inhibition, sodium-glucose cotransporter-2 inhibitors, mineralocorticoid receptor antagonists, lipid-lowering therapy, and management of anemia and mineral bone disease. Emerging therapies such as precision nephrology, anti-inflammatory agents, and artificial intelligence-assisted prediction models are also discussed. The article includes comparative pharmacological data, monitoring strategies, schematic graphical representations, and evidence-based recommendations aligned with KDIGO 2024 guidance.

**Key Words:** Chronic kidney disease, CKD, nephrology, SGLT2 inhibitors, ACE inhibitors, renal protection, KDIGO 2024, dialysis prevention, hypertension, diabetic kidney disease, glomerular filtration rate (eGFR), renin-angiotensin-aldosterone system inhibition.

## I. INTRODUCTION

Chronic kidney disease is defined by abnormalities in kidney structure or function persisting for more than three months, with

implications for health. CKD is classified based on estimated glomerular filtration rate (eGFR) and albuminuria. Diabetes mellitus and hypertension remain the leading causes globally. CKD contributes significantly to cardiovascular disease, electrolyte disturbances, anemia, metabolic acidosis, and end-stage renal disease (ESRD). Early recognition and aggressive risk-factor modification are essential for improving patient outcomes. The KDIGO 2024 guideline emphasizes integrated care models, individualized treatment plans, risk prediction equations, and earlier implementation of renoprotective therapies. Modern management aims not only to delay progression but also to reduce cardiovascular mortality and improve quality of life.<sup>1</sup>

## II. LIFESTYLE INTERVENTION

### 1. Dietary Modification:

- Sodium restriction to less than 2 g/day reduces blood pressure and proteinuria.
- Moderate protein intake (0.6–0.8 g/kg/day in advanced CKD) may delay progression.
- Potassium and phosphate restriction should be individualized.
- Mediterranean and plant-based diets are associated with improved cardiovascular outcomes.

### 2. Physical Activity:

Regular aerobic exercise improves insulin sensitivity, blood pressure control, and cardiovascular fitness.

### 3. Weight Reduction:

Obesity accelerates CKD progression through hyperfiltration and inflammation. Structured weight-loss interventions are beneficial.<sup>2</sup>

### 4. Smoking Cessation:

Smoking contributes to endothelial dysfunction and accelerated renal decline.

5. Fluid and Alcohol Management:  
 Fluid intake should be individualized. Excess alcohol consumption worsens hypertension and renal injury.<sup>3</sup>

### III. PHARMACOLOGICAL THERAPY

1. Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors:

ACE inhibitors and ARBs remain foundational therapies for albuminuric CKD. They reduce intraglomerular pressure and proteinuria.

2. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors:

Agents such as dapagliflozin and empagliflozin significantly reduce CKD progression and cardiovascular events.

3. Non-Steroidal Mineralocorticoid Receptor Antagonists:

Finerenone reduces albuminuria and cardiovascular

risk in diabetic CKD.

4. Glycemic Control:  
 HbA1c targets should be individualized. Metformin remains first-line therapy in appropriate patients with preserved eGFR.<sup>4</sup>

5. Lipid-Lowering Therapy:  
 Statins reduce cardiovascular morbidity in CKD patients not requiring dialysis.

6. Anemia Management:  
 Iron supplementation and erythropoiesis-stimulating agents are used based on iron indices and hemoglobin levels.

7. Mineral Bone Disease Management:  
 Phosphate binders, vitamin D analogs, and calcimimetics are used in selected patients.

8. Metabolic Acidosis:  
 Oral sodium bicarbonate therapy may slow progression in patients with low serum bicarbonate.<sup>5</sup>

Figure 1. Estimated distribution of CKD stages in the adult population





Figure 2. Common etiologies contributing to chronic kidney disease

Major Causes of CKD



**IV. MONITORING AND MANAGEMENT**

Routine monitoring is essential in CKD management:

- eGFR and urine albumin-to-creatinine ratio every 3–6 months.
- Blood pressure monitoring with target <130/80 mmHg in most patients.
- Periodic assessment of serum potassium, bicarbonate, calcium, phosphate, and hemoglobin.

- Cardiovascular risk assessment and vaccination review.

- Early nephrology referral in rapidly progressive CKD, refractory hypertension, or severe albuminuria.

Renal replacement therapy planning should begin in advanced CKD (stage 4–5). Shared decision-making regarding dialysis modality and kidney transplantation is recommended.<sup>6</sup>

**V. MEDICATION COMPARISON TABLE**

Drug Class	Examples	Primary Benefit	Major Adverse Effects	Clinical Role
ACE Inhibitors/ARBs	Enalapril, Losartan	Reduce proteinuria	Hyperkalemia, cough	First-line in albuminuric CKD
SGLT2 Inhibitors	Dapagliflozin, Empagliflozin	Renoprotection	Genital infections	Delay CKD progression
MRAs	Finerenone	Reduce albuminuria	Hyperkalemia	Diabetic CKD
Statins	Atorvastatin	Reduce CV risk	Myopathy	Cardiovascular prevention
ESA Therapy	Epoetin alfa	Treat anemia	Hypertension	CKD-related anemia <sup>7</sup>

**VI. FUTURE DIRECTIONS**

Future CKD management will likely focus on precision medicine and biomarker-guided therapy. Emerging areas include:

- Novel anti-inflammatory and anti-fibrotic agents.
- Artificial intelligence for risk prediction and

progression modeling.

- Gut microbiome modulation to reduce uremic toxins.
- Regenerative medicine and stem-cell therapies.
- Expanded use of wearable technology and tele-nephrology.

The KDIGO 2024 guideline also highlights the importance of multidisciplinary care, equitable healthcare access, and patient-reported outcomes.<sup>8</sup>

Disease.arXiv. 2025. Discusses machine learning and predictive modeling in CKD progression.

## VII. CONCLUSION

CKD management has undergone substantial transformation with the advent of evidence-based renoprotective therapies. Early diagnosis, lifestyle optimization, strict blood pressure control, and modern pharmacological interventions significantly improve renal and cardiovascular outcomes. Integration of SGLT2 inhibitors, RAAS blockade, and individualized patient-centered care now forms the cornerstone of therapy. Continued research into novel therapies and precision nephrology promises to further reduce the global burden of CKD.

## REFERENCE

- [1]. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Guideline 2024.
- [2]. **Levin A, et al.** Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD. Kidney International. 2024.
- [3]. **Brenner BM, et al. Brenner and Rector's The Kidney.** 11th Edition Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. New England Journal of Medicine. 2001;345:861–869. DOI: 10.1056/NEJMoa011161. Landmark evidence supporting ARBs in diabetic nephropathy.
- [4]. **Lewis EJ, Hunsicker LG, Bain RP, Rohde RD.** Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy. New England Journal of Medicine. 1993;329:1456–1462. DOI: 10.1056/NEJM19931113291904. Classic ACE inhibitor nephroprotection trial.
- [5]. National Kidney Foundation. KDOQI Clinical Practice Guidelines.
- [6]. **Perkovic V, et al.** Dapagliflozin and Prevention of Adverse Outcomes in CKD. N Engl J Med.
- [7]. **Heerspink HJL, et al.** SGLT2 inhibitors in CKD management, Dapagliflozin in Patients with Chronic Kidney Disease, Demonstrated reduced CKD progression and mortality in diabetic and non-diabetic CKD.
- [8]. **Fang Y, Nestor JG, Ta CN, et al.** A Method for Characterizing Disease Progression from Acute Kidney Injury to Chronic Kidney